140 related articles for article (PubMed ID: 26529120)
21. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
Rankin AM; Faller DV; Spanjaard RA
Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
[TBL] [Abstract][Full Text] [Related]
22. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis.
Kumar A; Roy S; Tripathi S; Sharma A
J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809
[TBL] [Abstract][Full Text] [Related]
23. New dimeric carbazole-benzimidazole mixed ligands for the stabilization of human telomeric G-quadruplex DNA and as telomerase inhibitors. A remarkable influence of the spacer.
Maji B; Kumar K; Muniyappa K; Bhattacharya S
Org Biomol Chem; 2015 Aug; 13(30):8335-48. PubMed ID: 26149178
[TBL] [Abstract][Full Text] [Related]
24. Telomeres and telomerase as targets for anticancer drug development.
Olaussen KA; Dubrana K; Domont J; Spano JP; Sabatier L; Soria JC
Crit Rev Oncol Hematol; 2006 Mar; 57(3):191-214. PubMed ID: 16469501
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, antiproliferative activities and telomerase inhibition evaluation of novel asymmetrical 1,2-disubstituted amidoanthraquinone derivatives.
Lee CC; Huang KF; Lin PY; Huang FC; Chen CL; Chen TC; Guh JH; Lin JJ; Huang HS
Eur J Med Chem; 2012 Jan; 47(1):323-36. PubMed ID: 22100139
[TBL] [Abstract][Full Text] [Related]
26. Potential human cholesterol esterase inhibitor design: benefits from the molecular dynamics simulations and pharmacophore modeling studies.
John S; Thangapandian S; Lee KW
J Biomol Struct Dyn; 2012; 29(5):921-36. PubMed ID: 22292952
[TBL] [Abstract][Full Text] [Related]
27. Telomere inhibition and telomere disruption as processes for drug targeting.
Rezler EM; Bearss DJ; Hurley LH
Annu Rev Pharmacol Toxicol; 2003; 43():359-79. PubMed ID: 12540745
[TBL] [Abstract][Full Text] [Related]
28. 2,7-Disubstituted amidofluorenone derivatives as inhibitors of human telomerase.
Perry PJ; Read MA; Davies RT; Gowan SM; Reszka AP; Wood AA; Kelland LR; Neidle S
J Med Chem; 1999 Jul; 42(14):2679-84. PubMed ID: 10411488
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of novel 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one derivatives as telomerase inhibitors.
Liu XH; Jia YM; Song BA; Pang ZX; Yang S
Bioorg Med Chem Lett; 2013 Feb; 23(3):720-3. PubMed ID: 23265905
[TBL] [Abstract][Full Text] [Related]
30. Symmetrical bisbenzimidazoles with benzenediyl spacer: the role of the shape of the ligand on the stabilization and structural alterations in telomeric G-quadruplex DNA and telomerase inhibition.
Bhattacharya S; Chaudhuri P; Jain AK; Paul A
Bioconjug Chem; 2010 Jul; 21(7):1148-59. PubMed ID: 20536245
[TBL] [Abstract][Full Text] [Related]
31. Human telomerase reverse transcriptase (hTERT): a target molecule for the treatment of cisplatin-resistant tumors.
Park YP; Kim KD; Kang SH; Yoon DY; Park JW; Kim JW; Lee HG
Korean J Lab Med; 2008 Dec; 28(6):430-7. PubMed ID: 19127107
[TBL] [Abstract][Full Text] [Related]
32. Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones.
Perry PJ; Reszka AP; Wood AA; Read MA; Gowan SM; Dosanjh HS; Trent JO; Jenkins TC; Kelland LR; Neidle S
J Med Chem; 1998 Nov; 41(24):4873-84. PubMed ID: 9822556
[TBL] [Abstract][Full Text] [Related]
33. Telomerase Inhibition by a New Synthetic Derivative of the Aporphine Alkaloid Boldine.
Kazemi Noureini S; Kheirabadi M; Masoumi F; Khosrogerdi F; Zarei Y; Suárez-Rozas C; Salas-Norambuena J; Kennedy Cassels B
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29671783
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and SARs of novel telomerase inhibitors based on BIBR1532.
Liu C; Zhou H; Sheng XB; Liu XH; Chen FH
Bioorg Chem; 2020 Sep; 102():104077. PubMed ID: 32682156
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan moiety as potential anticancer agents.
Zhang XM; Qiu M; Sun J; Zhang YB; Yang YS; Wang XL; Tang JF; Zhu HL
Bioorg Med Chem; 2011 Nov; 19(21):6518-24. PubMed ID: 21962523
[TBL] [Abstract][Full Text] [Related]
36. Virtual Screening with Docking Simulations and Biochemical Evaluation of VHY Phosphatase Inhibitors.
Park H; Lee HS; Kim SJ
Chem Pharm Bull (Tokyo); 2015; 63(10):807-11. PubMed ID: 26423037
[TBL] [Abstract][Full Text] [Related]
37. Anticancer therapy targeting telomeres and telomerase : current status.
Parkinson EK; Minty F
BioDrugs; 2007; 21(6):375-85. PubMed ID: 18020621
[TBL] [Abstract][Full Text] [Related]
38. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines.
Parsch D; Brassat U; Brümmendorf TH; Fellenberg J
Cancer Invest; 2008 Jul; 26(6):590-6. PubMed ID: 18584350
[TBL] [Abstract][Full Text] [Related]
39. Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors.
Read M; Harrison RJ; Romagnoli B; Tanious FA; Gowan SH; Reszka AP; Wilson WD; Kelland LR; Neidle S
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4844-9. PubMed ID: 11309493
[TBL] [Abstract][Full Text] [Related]
40. Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells.
Meng E; Taylor B; Ray A; Shevde LA; Rocconi RP
Gynecol Oncol; 2012 Mar; 124(3):598-605. PubMed ID: 22115853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
